There are 12 papers on fasting C-peptide in aging research: 6 trials and 5 observational studies in people.
12 papers study it23 more mention it9 findings
3 new papers in 30 daysSee all 35 papers on fasting C-peptide
“Logistic regression revealed that knee extension strength, fasting C-peptide (F-CPR) level and dorsiflexion strength were independent predictors of falls.”
- Human trial6
- Humans5
Interventions
5Tirzepatide
downin humans1
1 study
Tirzepatide
downin humans1
Tirzepatide decreases fasting C-peptide in humans (compared with an increase of C-peptide with semaglutide 1 mg) (5.2%-6.0% reduction with tirzepatide 10 and 15 mg; 3.3% increase with semaglutide 1 mg).
“Tirzepatide 10 and 15 mg resulted in a significant reduction in both fasting C-peptide (5.2%-6.0%)”
Human trialcompared with an increase of C-peptide with semaglutide 1 mg10 and 15 mg once weekly40 weeks
The Journal of clinical endocrinology and metabolism
Tirzepatide decreases fasting C-peptide in humans (5.2%-6.0% compared with the observed increase with semaglutide 1 mg (3.3%)).
“Greater and significant reductions in fasting C-peptide were seen with tirzepatide 10 and 15 mg (5.2%-6.0%) compared with the observed increase with semaglutide 1 mg (3.3%) (P <.05) at week 40.”
Human trial40-week
The Journal of clinical endocrinology and metabolism
GLP-1 receptor agonists
upin humans1
1 study
GLP-1 receptor agonists
upin humans1
GLP-1 receptor agonists are linked with higher fasting C-peptide in humans (combined with basal insulin, after glucose profiles improved) (from 0.65±0.36 to 1.03±0.55 ng/mL).
“Soon after daily glucose profiles were improved, F-CPR was 1.03±0.55 (0.30~1.94) ng/mL.”
Humanscombined with basal insulin, after glucose profiles improvedfemalesn = 7
21-PUB: GLP-1 Receptor Agonist–Based Therapy in Early Type 1 Diabetes
Diabetes
Liraglutide plus metformin
upin humans1
1 study
Liraglutide plus metformin
upin humans1
Liraglutide plus metformin is linked with higher fasting C-peptide in humans (compared with liraglutide plus acarbose).
“The fasting C-peptide and 2-h postprandial C-peptide levels in group A after treatment were higher than those in group B (P<0.05).”
Humanscompared with liraglutide plus acarbosen = 88
American journal of translational research
Vildagliptin
upin humans1
1 study
Vildagliptin
upin humans1
Vildagliptin increases fasting C-peptide in humans.
“which increased fasting C-peptide level greater than the other two drugs”
Human trialn = 30
Life sciences
Sitagliptin
upin humans1
1 study
Sitagliptin
upin humans1
Sitagliptin increases fasting C-peptide in humans (combined with CSII versus CSII alone).
“FC-P (Fasting c-peptide) levels in group C and group B were significantly higher than those in group A”
Human trialcombined with CSII versus CSII alonetwo weeks
Journal of biological regulators and homeostatic agents
Associations
3Glycemic response
upin humans1OR 2.58
1 study
Glycemic response
upin humans1OR 2.58
Fasting C-peptide predicts glycemic response in humans (Type 2 diabetes; response defined as an HbA1c reduction of at least 1.0 percentage point) (Adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001; AUC = 0.805; exploratory cut-off 2.33 ng/mL).
“Baseline C-peptide independently predicted glycemic response (adjusted OR = 2.58 per 0.5 ng/mL increase; p < 0.001)”
HumansType 2 diabetes; response defined as an HbA1c reduction of at least 1.0 percentage pointMean follow-up of 156 daysn = 196
Medicina (Kaunas, Lithuania)
DPP-4 inhibitors
upin humans1
1 study
DPP-4 inhibitors
upin humans1
DPP-4 inhibitors are associated with fasting C-peptide in humans (Type 2 diabetes; compared with SGLT2 inhibitor therapy) (Changes: 0.18 ± 0.44 vs. 0.03 ± 0.38 ng/mL; between-group p = 0.010; adjusted β = 0.149, p = 0.013).
“DPP-4 inhibitor therapy remained independently associated with higher follow-up C-peptide (adjusted β = 0.149; p = 0.013).”
HumansType 2 diabetes; compared with SGLT2 inhibitor therapyMean follow-up of 156 daysn = 196
Medicina (Kaunas, Lithuania)
Falls
upin humans1
1 study
Falls
upin humans1
Fasting C-peptide predicts falls in humans (type 2 diabetes).
“Logistic regression revealed that knee extension strength, fasting C-peptide (F-CPR) level and dorsiflexion strength were independent predictors of falls.”
Humanstype 2 diabetesone year after dischargen = 226
Exploratory analysis using machine learning of predictive factors for falls in type 2 diabetes
Scientific reports